James Whytock Joyce Simon

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
8076 Background: In one report of 144 patients (pts) with a variety of tumor types (27% lung cancer), 26% of pts received chemotherapy (chemo) within the last month (mo) of life (Aragon-Ching et al. Proc ASCO 22: #3119, 2003). For advanced (adv) NSCLC, 2nd-line treatment (tx) is now considered standard of care and 3rd-line tx was recently approved. With(More)
We observed three children, aged 1 year 8 months to 9 years 7 months, in whom herpes simplex blepharoconjunctivitis resolved promptly without treatment. A fourth child, 8 years old, developed probable toxic manifestations from topical vidarabine. These manifestations, as well as the blepharoconjunctivitis, resolved when the medication was discontinued.(More)
16040 Background: The treatment of advanced (adv) colorectal cancer (CRC) is currently a moving target due to the availability of new agents and a multitude of clinical trials. It is of interest to see how community oncologists have responded to these changes, and what effect they have had on outcome (survival). We report the chemotherapy treatment (tx) of(More)
It's amazing, but outside of a few minor casualties where the turkey got the better of the hatchet, everybody seems to have had a wonderful time over the vacation. Isn't it wonderful to be back to school working again? Now we begin thinking about Christmas and it's only 18 more days 'till we have another vacation. Speaking of the glorious season leads us to(More)
8275 Background: Though D has been available for a year, no comparative trials between EPO and D have been presented. Also, there are few effectiveness evaluations aimed at highlighting differences between the two. Therefore, evidence supporting product selection rational is scant. NSCLC is a tumor type in which EPO treatment (tx) is common. We report an(More)
6017 Background: In contrast to clinical trials, standard (ie WHO) AE criteria are rarely used in community practice (CP). Because focusing on clinical decisions has more utility, we define a clinically significant (sig) AE as one resulting in deviation from planned chemo delivery. AEs are broadly categorized as tox resulting in a regimen change, a dose(More)
  • 1